Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers
about
Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and managementRationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the EvidenceAn international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.Differences in Uptake of Risk Reduction Strategies Among Underserved PopulationsExperience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation CarrierThe double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screeningHealth Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?Considerations for the Treatment of Young Patients with Breast Cancer.Risk-reducing salpingectomy: Let us be opportunistic.Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report.Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view.What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Fertility preservation in gynaecologic cancers.Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double EffectThe 10th Oxbridge varsity medical ethics debate-should we fear the rise of direct-to-consumer genetic testing?Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of BreaSurgery for , TP53 and PALB2: a literature reviewReal-world health services utilisation and outcomes after and testing in Ontario, Canada: the What Comes Next Cohort Study protocolPrevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening†
P2860
Q26747160-FFC5D1C5-E3BE-4F87-958E-C69085DDF519Q30250107-E8D520D9-B8C8-4B1B-9EB4-8BA9AC81E419Q33901361-B1296FBD-2D37-48E4-AF70-5CD257592F81Q36240959-973CE63E-E541-47DA-A0E1-398B572A4383Q36313479-EE085850-A8E6-448C-BB5B-1A89EDD83CABQ36541035-14A79B67-6B08-4854-AEBD-D8623A9FD5B5Q37056948-81B6D480-214F-4779-8F58-8C449C97E3BBQ37058193-93AAB12D-6211-4474-B744-36628E5F5A13Q38868393-8C29C3FC-EE8F-4EBB-80B4-CDC23E3A6932Q38932067-469A0265-01AC-443E-BF8F-87E95AD4D439Q39196159-670C62ED-7FDD-493E-9CCF-9478888E609FQ41035840-F566A8A7-9A9C-451A-BB46-C6F14BF384A5Q41161920-54009376-6421-4561-BCF7-6EE2B7696E96Q42552179-387ACD27-B13A-409D-8F35-97741B40C324Q47127058-5E6D70A1-C62B-47D9-9F00-249695626220Q47189965-8B33DA11-0352-4573-A0F2-71CC5C797806Q47762116-C240FE46-F527-48B1-B3AD-05718ABC0DCBQ47958061-F9CD7092-255F-4205-821A-7FCAE6CFD1A6Q48110433-FB4F8305-4822-4CD5-A097-58EF68BF671FQ49957633-612D6707-C19B-4BDC-86B6-EEC94AE6095BQ55002454-013198B3-DEFA-458C-8ABD-AE68C89E12C5Q55377222-6CDBB7DC-1497-4233-A966-09A6F8EE0B47Q57137351-2B2B24C2-B2E0-4D2B-8814-3E24B485A2F3Q58106428-89F2598E-384B-42D9-860D-EE0FE597F562Q58124814-B8920C2D-BFEA-42E0-AC7C-BDA998FF394FQ58696819-353469BA-087E-4B4B-A73F-867C3CFD252BQ58764940-709A67BF-5278-4537-93EC-237A4C3F8FD9Q59273721-B6A2E083-B32F-44DA-9DEE-D47A0D7D0547
P2860
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@ast
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@en
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@nl
type
label
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@ast
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@en
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@nl
prefLabel
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@ast
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@en
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@nl
P2093
P2860
P31
P50
P3181
P1433
P1476
Risk-reducing salpingo-oophore ...... 1 and BRCA 2 mutation carriers
@en
P2093
Francesca De Felice
Pierluigi Benedetti Panici
Vincenzo Tombolini
P2860
P2888
P3181
P356
10.1186/S12905-014-0150-5
P407
P5008
P577
2014-12-12T00:00:00Z
P5875
P6179
1025883240